423 related articles for article (PubMed ID: 32244756)
41. Targeting T cell immunometabolism for cancer immunotherapy; understanding the impact of the tumor microenvironment.
Mockler MB; Conroy MJ; Lysaght J
Front Oncol; 2014; 4():107. PubMed ID: 24904823
[TBL] [Abstract][Full Text] [Related]
42. Glutamine blockade induces divergent metabolic programs to overcome tumor immune evasion.
Leone RD; Zhao L; Englert JM; Sun IM; Oh MH; Sun IH; Arwood ML; Bettencourt IA; Patel CH; Wen J; Tam A; Blosser RL; Prchalova E; Alt J; Rais R; Slusher BS; Powell JD
Science; 2019 Nov; 366(6468):1013-1021. PubMed ID: 31699883
[TBL] [Abstract][Full Text] [Related]
43. Altered cancer metabolism in mechanisms of immunotherapy resistance.
Ramapriyan R; Caetano MS; Barsoumian HB; Mafra ACP; Zambalde EP; Menon H; Tsouko E; Welsh JW; Cortez MA
Pharmacol Ther; 2019 Mar; 195():162-171. PubMed ID: 30439456
[TBL] [Abstract][Full Text] [Related]
44. Unraveling the crosstalk between melanoma and immune cells in the tumor microenvironment.
Marzagalli M; Ebelt ND; Manuel ER
Semin Cancer Biol; 2019 Dec; 59():236-250. PubMed ID: 31404607
[TBL] [Abstract][Full Text] [Related]
45. Immune checkpoint inhibitor combinations: Current efforts and important aspects for success.
Kon E; Benhar I
Drug Resist Updat; 2019 Jul; 45():13-29. PubMed ID: 31382144
[TBL] [Abstract][Full Text] [Related]
46. The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment.
Poon E; Mullins S; Watkins A; Williams GS; Koopmann JO; Di Genova G; Cumberbatch M; Veldman-Jones M; Grosskurth SE; Sah V; Schuller A; Reimer C; Dovedi SJ; Smith PD; Stewart R; Wilkinson RW
J Immunother Cancer; 2017 Aug; 5(1):63. PubMed ID: 28807001
[TBL] [Abstract][Full Text] [Related]
47. The non-T-cell-inflamed tumor microenvironment: contributing factors and therapeutic solutions.
Horton BL; Spranger S
Emerg Top Life Sci; 2017 Dec; 1(5):447-456. PubMed ID: 33525802
[TBL] [Abstract][Full Text] [Related]
48. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
[TBL] [Abstract][Full Text] [Related]
49. Tumor-intrinsic oncogene pathways mediating immune avoidance.
Spranger S; Gajewski TF
Oncoimmunology; 2016 Mar; 5(3):e1086862. PubMed ID: 27141343
[TBL] [Abstract][Full Text] [Related]
50. Linking tumor glycolysis and immune evasion in cancer: Emerging concepts and therapeutic opportunities.
Ganapathy-Kanniappan S
Biochim Biophys Acta Rev Cancer; 2017 Aug; 1868(1):212-220. PubMed ID: 28400131
[TBL] [Abstract][Full Text] [Related]
51. Cancer Immunotherapy by Blocking Immune Checkpoints on Innate Lymphocytes.
Pesce S; Trabanelli S; Di Vito C; Greppi M; Obino V; Guolo F; Minetto P; Bozzo M; Calvi M; Zaghi E; Candiani S; Lemoli RM; Jandus C; Mavilio D; Marcenaro E
Cancers (Basel); 2020 Nov; 12(12):. PubMed ID: 33255582
[TBL] [Abstract][Full Text] [Related]
52. Tumor microenvironmental influences on dendritic cell and T cell function: A focus on clinically relevant immunologic and metabolic checkpoints.
Hargadon KM
Clin Transl Med; 2020 Jan; 10(1):374-411. PubMed ID: 32508018
[TBL] [Abstract][Full Text] [Related]
53. Targeting Cancer Metabolism to Improve Outcomes with Immune Checkpoint Inhibitors.
Fatima Z; Abonofal A; Stephen B
J Immunother Precis Oncol; 2023 May; 6(2):91-102. PubMed ID: 37214204
[TBL] [Abstract][Full Text] [Related]
54. Potential roles of sex-linked differences in obesity and cancer immunotherapy: revisiting the obesity paradox.
Vick LV; Rosario S; Riess JW; Canter RJ; Mukherjee S; Monjazeb AM; Murphy WJ
NPJ Metab Health Dis; 2024; 2(1):5. PubMed ID: 38800540
[TBL] [Abstract][Full Text] [Related]
55. Spotlight on GOT2 in Cancer Metabolism.
Kerk SA; Garcia-Bermudez J; Birsoy K; Sherman MH; Shah YM; Lyssiotis CA
Onco Targets Ther; 2023; 16():695-702. PubMed ID: 37635751
[TBL] [Abstract][Full Text] [Related]
56. Editorial overview: Intrinsically tied: metabolism and immune cell function.
Hiller K; Brenner D
Curr Opin Biotechnol; 2021 Apr; 68():iii-v. PubMed ID: 33879393
[No Abstract] [Full Text] [Related]
57. Lipids in the tumor microenvironment: From cancer progression to treatment.
Corn KC; Windham MA; Rafat M
Prog Lipid Res; 2020 Nov; 80():101055. PubMed ID: 32791170
[TBL] [Abstract][Full Text] [Related]
58. Targeting Metabolism to Improve the Tumor Microenvironment for Cancer Immunotherapy.
Bader JE; Voss K; Rathmell JC
Mol Cell; 2020 Jun; 78(6):1019-1033. PubMed ID: 32559423
[TBL] [Abstract][Full Text] [Related]
59. Effects of dietary intervention on human diseases: molecular mechanisms and therapeutic potential.
Xiao YL; Gong Y; Qi YJ; Shao ZM; Jiang YZ
Signal Transduct Target Ther; 2024 Mar; 9(1):59. PubMed ID: 38462638
[TBL] [Abstract][Full Text] [Related]
60. Transcriptome Sequencing Unveils a Molecular-Stratification-Predicting Prognosis of Sarcoma Associated with Lipid Metabolism.
Hong Y; Zhang L; Lin W; Yang Y; Cao Z; Feng X; Yu Z; Gao Y
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338920
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
